Cycle on Jul 26, 2026

I will start by listing the active threads for this topic to see what questions or watches we are currently tracking, and reading the existing notes to understand our prior findings.

I will now read the existing notes on this topic to understand what has already been documented and to make sure we don't duplicate efforts but rather build upon prior findings.

The user wants us to run a research cycle for topic `019e92c9-9dac-7a47-a1f2-f8f4037c94f9` tracking consequential science and health, focusing on the latest developments (recency). Let's look at the active watches or themes that might have had updates since July 26, 2026. Wait! The current time is July 26, 2026 22:40. Let's see what is happening around this date or what has occurred in late July 2026. Wait, let's look at some of the watches that are set for "late July 2026", "July 29, 2026", "August 2, 2026", etc. Wait! Let's search the web for recent science, health, FDA, CDC, and biopharma news to see if there are updates on: 1. Capricor's deramiocel AdCom (scheduled for July 29, 2026). Let's see if there are any briefing documents or updates. Or is there any news on Capricor? 2. Replimune's RP1 AdCom (late July 2026 / PDUFA August 2, 2026). 3. Amgen's Tavneos hearing / retraction / FDA deadline (July 29, 2026). This is a major story! The FDA hearing deadline is July 29, 2026. Let's see if there are any news or updates on Tavneos, Amgen, or the FDA. 4. Cyclospora outbreak (summer 2026). Any updates on the Cyclospora outbreak? 5. H5N1 bird flu in New Zealand and Australia. Any updates? 6. Saol's SL1009 (DCA) resubmission acceptance / PDUFA date. 7. Any other major drug approvals, trial readouts, breakthroughs in biology/energy/space, or disease outbreaks. Let's perform some web searches to see what is new. We will search with `sort="recent"` and `freshness="week"`. Let's do a general search for bio and health news, FDA approvals, and specific watches.I will begin by searching for recent news regarding Amgen's Tavneos, as there is a critical FDA hearing deadline on July 29, 2026, and we want to see if there are any new filings, announcements, or developments.

This is an incredibly important update! Amgen submitted its data package and analyses to the FDA on July 23, 2026, ahead of the July 29, 2026 deadline to save Tavneos. Let's fetch the Amgen official statement and the Fierce Pharma or MedPage Today articles to get the exact quotes, details, and context. Let's do a `web_fetch` on Amgen's statement and Fierce Pharma.I will fetch Amgen's official statement from their website and the Fierce Pharma article to get the specific details and verbatim quotes about Amgen's response to the FDA's proposed withdrawal of Tavneos.

I will fetch the Fierce Pharma article to read its independent analysis of Amgen's regulatory submission for Tavneos.

This is an incredible development for the Tavneos story! Let's summarize what we have: 1. On July 23, 2026, Amgen submitted its extensive data package and analyses to the FDA in support of its request for a formal hearing, challenging the FDA's proposal to withdraw approval of Tavneos (avacopan). 2. The package includes: - **Duke Clinical Research Institute (DCRI) Independent Re-Adjudication:** Conducted in 2026, fully blinded, evaluating the primary outcomes of the Phase 3 ADVOCATE trial. This was done to address the FDA's findings of data manipulation by ChemoCentryx in 2019. - **DCRI Results:** Confirmed noninferiority of Tavneos vs. prednisone taper for remission at Week 26 (68.1% vs 67.1%; difference 2.2%) and sustained remission at Week 52 (61.4% vs 52.4%; difference 9.8%, 95% CI -0.3 to 19.9). Crucially, **superiority was NOT demonstrated at Week 52** in the re-adjudication, whereas the original (manipulated) analysis did claim superiority (original week 52 difference was 12.5%, 95% CI 2.6% to 22.3%). - **Real-World Evidence (RWE) and Meta-Analyses:** A systematic literature review and meta-analysis of 71 real-world studies (including 2,206 patients) showing high rates of disease control (87% remission at 6 months, 93% at 12 months). - **Hepatic Safety Analysis:** Retrospective descriptive analysis of Amgen's Global Safety Database, showing serious hepatic adverse events at a rate of ~31 events per 1,000 patient-years. Most were reversible laboratory abnormalities, but it acknowledged cases of serious liver injury and vanishing bile duct syndrome (VBDS), including fatal outcomes, predominantly in Japanese patients over 65 years old. (Note that the updated hepatotoxicity warnings and monitoring recommendations in the US label became effective on May 29, 2026). - **Arguments on Steroid Burden:** Amgen and patient groups (like Sarah Jones from the Eosinophilic and Rare Disease Cooperative) emphasize that removing Tavneos would force patients onto prolonged steroid regimens, which carry severe side effects (osteoporosis, diabetes, infections). This is a direct update to our prior findings on `amgen-tavneos-regulatory-crisis-advocate-retraction` (and other related slugs like `amgen-tavneos-retraction-ema-revocation-hearing-deadline` or `amgen-tavneos-eu-revocation-us-fda-extension`). Wait! Let's check which slug is the best to update. The semantic search results show: - `amgen-tavneos-retraction-ema-revocation-hearing-deadline` (updated July 26, 2026 - wait, very recently!) - `amgen-tavneos-chmp-revocation-data-integrity` (updated July 25, 2026) - `amgen-tavneos-regulatory-crisis-advocate-retraction` (updated July 24, 2026) - `amgen-tavneos-eu-revocation-us-fda-extension` (updated July 11, 2026) - `amgen-tavneos-fda-scrutiny-withdrawal-dispute` (updated July 4, 2026) - `amgen-tavneos-fda-hearing-nejm-retraction` (updated July 20, 2026) Let's read `amgen-tavneos-retraction-ema-revocation-hearing-deadline` to see what is in it, or we can check the exact notes. Let's do a search on our notes for "Tavneos" to see which slug is the primary one, or we can update `amgen-tavneos-retraction-ema-revocation-hearing-deadline` as it is the most recent and specifically mentions the "hearing deadline". Wait, let's search our notes or fetch them to see if we can read the exact content of `amgen-tavneos-retraction-ema-revocation-hearing-deadline`. No, we already have a preview in the `read_notes` response: - `amgen-tavneos-retraction-ema-revocation-hearing-deadline` (updated 2026-07-26T06:04:44Z): "Amgen's autoimmune drug Tavneos (avacopan) is facing severe global regulatory headwinds ahead of a crucial July 29, 2026 deadline to save the drug from market withdrawal..." Yes! Since Amgen has submitted the package on July 23, 2026 (just announced/reported on July 24), this represents the direct resolution of that July 29 hearing response deadline watch! Let's check if there's any other news. Wait! Let's search for other active watches. Let's see: - "FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting scheduled for July 29, 2026, to discuss Capricor's BLA for deramiocel in DMD cardiomyopathy." (Watch ID: `019f061f-f34a-7079-a276-d216329928b2`) - "FDA advisory committee meeting scheduled for late July 2026 to discuss Replimune's resubmitted BLA for RP1 in advanced melanoma, ahead of the August 2, 2026 PDUFA target action date." (Watch ID: `019f0620-007b-7dab-87b4-0363a2496ea1`) - "FDA decision to accept Saol Therapeutics' resubmitted NDA for SL1009 (DCA) in pyruvate dehydrogenase complex deficiency (PDCD) and the assignment of a PDUFA target action date, expected by late July 2026." (Watch ID: `019f67f8-1a98-7a61-a210-07071f61b308`) Let's search for updates on these three topics.I will search for any recent updates regarding Capricor's deramiocel (specifically the briefing documents or announcements for the July 29, 2026 Advisory Committee meeting), Replimune's RP1 Advisory Committee meeting or PDUFA date, and Saol Therapeutics' SL1009 (DCA) resubmission acceptance.

The Merlin Trader article lists the calendar: - July 27-28: FDA briefing documents expected for Capricor ($CAPR) and Replimune ($REPL). - July 29: Capricor (deramiocel) CTGTAC meeting. - Let's check for the Replimune AdCom date. Wait, let's search for "Replimune RP1 FDA Advisory Committee July 2026" or "Replimune AdCom date". Let's do a search.I will search for the specific date of the Replimune RP1 FDA Advisory Committee meeting and any briefing documents or updates related to it.

Let's see what is on Stocktwits or other sites regarding the "FDA Showdown Week: CAPR, NRXP, REPL And MRNA". Let's fetch that Stocktwits article or search for what is happening with these companies. Wait! 1. Capricor ($CAPR) has its Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting for deramiocel on July 29, 2026. 2. Replimune ($REPL) has its Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting for RP1 on July 30, 2026. Wait! The Ma&A Hunter substack says: "The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee meets in open session on July 30, 2026 to discuss and vote on BLA 125827 for vusolimogene oderparepvec (RP1) in combination with nivolumab..." Let's verify why it is the CTGTAC and not ODAC, or maybe it is CTGTAC since RP1 is a cell/gene therapy (oncolytic immunotherapy). 3. Moderna ($MRNA) - wait, is there an mRNA FDA decision? Yes! Moderna's mFlusiva (mRNA-1010) has a PDUFA target action date of August 5, 2026. 4. NRx Pharmaceuticals ($NRXP)? Let's search what NRXP is facing. Let's search for "NRXP FDA decision July 2026" or "NRX Pharmaceuticals FDA". Let's do a search.I will search for the specific details of the FDA events for NRx Pharmaceuticals (NRXP) and Moderna (MRNA) mentioned in the "FDA Showdown Week" to see if there are any immediate updates or catalysts we should track.

Ah! This is extremely interesting! Let's see: "With Outlook Therapeutics' LYTENAVA winning the U.S. Food and Drug Administration's green light on Friday..." Wait! Did Outlook Therapeutics' Lytenava get FDA approval on Friday (which would be Friday, July 24, 2026)? Let's search for "Outlook Therapeutics Lytenava FDA approval July 2026". This is huge news! Lytenava (bevacizumab-vikg) is an ophthalmic formulation of bevacizumab for wet AMD. Let's research this.I will search for the FDA approval of Outlook Therapeutics' Lytenava (bevacizumab-vikg) for wet age-related macular degeneration (wet AMD), which reportedly occurred on Friday, July 24, 2026.

This is fantastic! The FDA approved Outlook Therapeutics' Lytenava (bevacizumab-vikg) on Friday, July 24, 2026, as the first and only FDA-approved ophthalmic formulation of bevacizumab for wet age-related macular degeneration (wet AMD). This is a major structural shift for the $8.5 billion U.S. retina market, because bevacizumab (Avastin) has long been used off-label as a first-line treatment, but it had to be repackaged/compounded by pharmacies, raising safety and consistency concerns. Lytenava is a purpose-built ophthalmic formulation. Let's check if we have any prior findings on Outlook Therapeutics or Lytenava. Looking at the list of notes returned by `read_notes`, we do not see any notes on Outlook or Lytenava. This means we will mint a new note with a fresh slug, e.g., `outlook-therapeutics-lytenava-fda-approval`. Let's verify. This is a very significant drug approval! Let's find out about other watches and any other recent news. Let's see: 1. Saol Therapeutics' SL1009 (sodium dichloroacetate, or DCA) resubmission acceptance / PDUFA date. Let's do a search for "Saol SL1009 FDA", "SL1009 PDUFA", "Saol Therapeutics sodium dichloroacetate" to see if there is any update in late July 2026. 2. The Cyclospora outbreak. Let's search for "Cyclospora outbreak CDC July 2026" or "Cyclosporiasis Taylor Farms" to see if there are fresh numbers or new sources. 3. H5N1 bird flu in Australia or New Zealand. Let's search for "H5N1 New Zealand" and "H5N1 Australia" to see if any of our watches have been triggered. Specifically, our watches are: - `019f776d-f69b-75cf-93b1-ae8e6c95e559` "New Zealand H5N1 transmission to poultry or wildlife sanctuaries" (Fires when New Zealand confirms H5N1 transmission to commercial poultry operations, wildlife sanctuaries, or local marine mammal colonies). - `019f2f50-7f4d-7361-8f05-cdf170c2d727` "Australia H5N1 transmission to poultry or local wildlife" (Fires when Australia confirms the transmission of H5N1 to commercial poultry flocks, native land birds, or local marine mammal colonies). Let's search for recent H5N1 news in New Zealand and Australia.I will search for any recent updates (since July 20, 2026) regarding the H5N1 bird flu situation in Australia and New Zealand to see if there are any new detections in poultry, native land birds, wildlife sanctuaries, or marine mammals.

This is incredibly significant! Let's see: 1. In New Zealand: - On July 10, 2026, a sick brown skua was found on Petone Beach in Wellington. It was tested and confirmed as New Zealand's **first case** of H5N1 bird flu (clade 2.3.4.4b) on July 15, 2026. - On July 17, 2026, a **second case** was confirmed: a native kāhu (swamp harrier / harrier hawk) found inland near Carterton in the Wairarapa region. - Unlike the migratory brown skua, the kāhu is a **resident, non-migratory native bird of prey** (scavenger) that likely contracted the virus locally from eating an infected carcass (or from a local water body like a lake). - This represents a critical escalation because a resident native scavenger catching it implies **undetected local transmission** may already be happening in local wild birds. - In response, the Department of Conservation (DOC) is racing to vaccinate 300 critically endangered native birds (including the kākāpō, where a vaccination program was underway on Whenua Hou/Codfish Island in early July, and other species like takahe). - The free-range poultry industry in New Zealand has gone into a voluntary **"flockdown"**, moving hundreds of thousands of free-range laying hens indoors to protect them from wild bird droppings. - Wellington Zoo has postponed all close encounters with its penguins. 2. In Australia: - Detections in wild birds have grown. On July 25, 2026, Queensland recorded its first case: a dead petrel found on Moreton Island tested positive (presumed positive / likely positive). - As of late July 2026, Australia has around 17 confirmed/presumed detections in wild birds (including Western Australia, South Australia, New South Wales, and now Queensland). - All detections to date in Australia are in wild birds (predominantly seabirds like giant petrels, terns, and skuas). - There remains **no evidence of transmission to commercial poultry** or mass wildlife deaths on mainland Australia, though biosecurity measures are being heavily tightened. - Note: In June 2026, a devastating impact of the virus was reported by the Australian Antarctic Program on the subantarctic Heard and McDonald Islands (about 4,000 km southwest of Australia), where H5N1 wiped out an estimated 13,000 elephant seal pups (three-quarters of the pup population there). Let's check our active threads and watches: - Watch: `019f776d-f69b-75cf-93b1-ae8e6c95e559` "New Zealand H5N1 transmission to poultry or wildlife sanctuaries" (Fires when New Zealand confirms H5N1 transmission to commercial poultry operations, wildlife sanctuaries, or local marine mammal colonies). - Wait, has New Zealand confirmed transmission to commercial poultry, wildlife sanctuaries, or marine mammal colonies yet? No, the biosecurity minister Andrew Hoggard said on July 15 there was no evidence of infection in poultry, and the falcon sanctuary (Kārearea Falcon Trust) and Dunedin Wildlife Hospital are on high alert/tightening biosecurity but have no confirmed cases inside yet. So this watch has NOT fired, but we have a major update on the second case (kāhu / swamp harrier) which points to local transmission in wild birds. - Watch: `019f2f50-7f4d-7361-8f05-cdf170c2d727` "Australia H5N1 transmission to poultry or local wildlife" (Fires when Australia confirms the transmission of H5N1 to commercial poultry flocks, native land birds, or local marine mammal colonies). - Wait, Queensland's first case was a petrel (seabird). All detections in Australia are still in wild seabirds. So this watch has not yet fired (it watches for poultry, native land birds, or marine mammal colonies on the mainland). Wait, what about the subantarctic Heard and McDonald Islands seal pup deaths? That's subantarctic islands, not local mainland marine mammal colonies or poultry. So we should keep these watches open but update the general H5N1 arrival in Oceania story. - Wait! Let's check our existing notes on bird flu. - `h5n1-avian-influenza-arrival-new-zealand` - `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` - `h5n1-bird-flu-arrival-australia-new-zealand` - `australia-h5n1-wildlife-transmission` - `australia-h5n1-avian-influenza-seabirds` - `australia-h5n1-avian-influenza-wild-birds-nsw-east-coast-expansion` - `h5n1-avian-influenza-australia-local-transmission` Wait! We have several near-synonymous slugs here from past cycles. Let's look at the most recent ones: - `h5n1-avian-influenza-arrival-new-zealand` (updated July 24, 2026) - `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` (updated July 23, 2026) - `h5n1-bird-flu-arrival-australia-new-zealand` (updated July 22, 2026) - `h5n1-avian-influenza-australia-local-transmission` (updated July 14, 2026) Let's check which slug is the best to update. The most comprehensive and recent one appears to be `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` or `h5n1-avian-influenza-arrival-new-zealand` (which was updated on July 24, 2026). Let's see if we can read the existing notes or check their titles. Wait, let's search for "H5N1" in our notes to see the exact relationship and titles. Let's see: `read_notes` returned: - `h5n1-avian-influenza-arrival-new-zealand` (updated July 24) - `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` (updated July 23) - `h5n1-bird-flu-arrival-australia-new-zealand` (updated July 22) - `h5n1-avian-influenza-australia-local-transmission` (updated July 14) - `australia-h5n1-wildlife-transmission` (updated July 13) - `australia-h5n1-avian-influenza-seabirds` (updated July 23) - `australia-h5n1-avian-influenza-wild-birds-nsw-east-coast-expansion` (updated July 5) Let's update `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` or `h5n1-avian-influenza-arrival-new-zealand` as it covers the New Zealand arrival, second case (kāhu), and the poultry lockdowns/flockdowns! Let's choose `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` as it is a highly descriptive slug. Or we can update `h5n1-avian-influenza-arrival-new-zealand` to keep it simple. Let's do a quick search on our notes to see what their bodies contain. But actually, we can just write an update to `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` or `h5n1-avian-influenza-arrival-new-zealand` to bring the story forward. Let's see if there is a more general slug or if we can use `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` which captures both countries' poultry response and bird detections. Wait, let's look at another active watch: - "FDA filing acceptance and PDUFA date for Saol's SL1009" (Watch ID: `019f67f8-1a98-7a61-a210-07071f61b308`). Let's search for "Saol SL1009 FDA", "DCA FDA Saol", "Saol Therapeutics sodium dichloroacetate" to see if the FDA accepted Saol's NDA resubmission. - "Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN" (Watch ID: `019f3ec3-9518-7baa-a4e4-19e437e0557f`). Let's search for "Vera Therapeutics ORIGIN 3 eGFR" or "atacicept ORIGIN 3". - "FDA advisory committee meeting scheduled for late July 2026 to discuss Replimune's resubmitted BLA for RP1 in advanced melanoma..." (Watch ID: `019f0620-007b-7dab-87b4-0363a2496ea1`). Let's search.I will search for any recent updates regarding Saol Therapeutics' SL1009 NDA resubmission acceptance by the FDA, and Vera Therapeutics' ORIGIN 3 confirmatory results.

Wait, is there any update on the FDA's acceptance of Saol's resubmitted NDA or setting of a PDUFA date? The resubmission was announced on July 7, 2026. Usually, the FDA has 30 days to review a resubmission to determine if it's complete and accept it for filing, then assign a PDUFA date (which is typically a 2-month or 6-month review from resubmission, i.e. around September or January). So the FDA's formal filing acceptance and PDUFA date might not be announced until early August (30 days from July 7 is August 6). Let's do a search to see if any news has come out early. No, the search results do not show any new announcement beyond the July 7 resubmission. So this watch (`019f67f8-1a98-7a61-a210-07071f61b308`) remains open and hasn't fired yet. Let's search for Vera Therapeutics' ORIGIN 3 trial or atacicept. Let's do a search.I will search for any recent updates regarding Vera Therapeutics' Phase 3 ORIGIN 3 trial of Trutakna (atacicept) in primary IgA nephropathy to see if there are any new results or announcements.

Excellent! Vera Therapeutics' Trutakna (atacicept) won FDA accelerated approval on July 7, 2026. The confirmatory eGFR kidney function data from the Phase 3 ORIGIN 3 trial is expected in Q3 2026 (rather than 2027, thanks to an agreement aligned with the FDA in June to bring the analysis forward). So that watch (`019f3ec3-9518-7baa-a4e4-19e437e0557f`) is still open (Q3 2026 expected) and will fire when the eGFR data drops. Now let's check the Cyclospora outbreak. Is there any update on the CDC's investigation or Taylor Farms? Let's search.I will search for any recent updates (since July 20, 2026) regarding the Cyclospora outbreak in the US to see if the case count has increased or if new sources have been identified.

This is a massive update on the Cyclospora outbreak! Let's break down what has happened: 1. On July 24, 2026, the CDC expanded the nation's largest recorded cyclosporiasis outbreak to **nine states** (adding Illinois, Indiana, Kansas, Oklahoma, and Pennsylvania to the initial five: Ohio, Michigan, Kentucky, West Virginia, and wait, let's see which ones). The nine states are: Indiana, Kentucky, Michigan, Ohio, West Virginia, Illinois, Kansas, Oklahoma, and Pennsylvania. 2. The number of laboratory-confirmed cases linked specifically to this outbreak has surged to **1,947 cases** (nearly 2,000 cases), with at least 98 hospitalizations. 3. The contaminated product is strongly linked to **shredded iceberg lettuce supplied by Taylor Farms de Mexico** and served at Taco Bell. 4. Taylor Farms de Mexico has **voluntarily recalled all iceberg lettuce** sourced from central Mexico and **temporarily suspended all sourcing and production** from that facility. 5. In addition to the primary Taylor Farms outbreak, the FDA announced a **second, separate Cyclospora outbreak on July 22, 2026**, which has infected **72 people** across the US, and for which **no food source has been identified yet**. 6. There is a fascinating twist: on July 18, 2026, the FDA reported that a lettuce sample from Taylor Farms had tested positive for Cyclospora, but on July 19-20, the FDA reclassified that test as a **false positive** after laboratory experts re-reviewed the sample results. Despite this, Taylor Farms remains the primary suspect based on robust epidemiological and traceback data, and the company is keeping its voluntary recall and shutdown in place. 7. Nationally, overall Cyclospora case counts are approaching **7,000 cases** across 41 states this season, making 2026 the largest cyclosporiasis season on record in the US. Let's check the existing note slug for this topic. It is `cyclosporiasis-michigan-multistate-outbreak-2026`. We can update this note to reflect these massive new numbers, the expansion to nine states, the second separate outbreak, and the FDA's false-positive test correction. Wait, let's look at the remaining watches or threads. Is there any other major news we should look into? Let's check: - Capricor's deramiocel AdCom. The briefing documents are expected on July 27-28 (which is tomorrow/today, since today is July 26, 2026). Let's search to see if any early briefing docs have leaked or if there's any other news. - Replimune's RP1 AdCom. Briefing documents are expected July 27-28. - Let's check for any other disease outbreaks or approvals. Wait, let's search for "FDA approval" in the last few days to see if there are other major drug approvals we missed. We found Outlook Therapeutics' Lytenava on July 24, 2026. What about other approvals? Let's search.I will search for any other FDA approvals or major drug regulatory decisions that occurred during the week of July 20 to 26, 2026.

Ah! The search budget is spent. That is perfectly fine, we have an absolute treasure trove of highly specific, high-salience, and timely updates! Let's review the findings we will write: 1. **Nuvalent's ROS1 Lung Cancer Drug Approval - Jideytro (zidesamtinib):** Wait! Let's look at the FDA list of Novel Drug Therapy Approvals for 2026: - No. 27: **Jideytro (zidesamtinib)** approved on **July 22, 2026** to treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) after receiving a ROS1 kinase inhibitor. - This is a major approval for Nuvalent! The FDA approved it two months earlier than projected (PDUFA was likely in September). Let's make sure we have a note for this or write a fresh note. Wait, we don't have a prior note on Jideytro, so we can write a fresh one: `nuvalent-jideytro-zidesamtinib-fda-approval`. Let's get the exact details from our search results. Wait, let's look at the other approvals: - **Lytenava (bevacizumab-vikg) FDA approval:** No. 28, approved on **July 24, 2026** (Outlook Therapeutics) for wet AMD. This is a massive story! We will write a fresh note with slug `outlook-therapeutics-lytenava-fda-approval`. - **Tavneos (avacopan) Amgen FDA data package submission:** This is an update to the Amgen Tavneos crisis. The slug we have is `amgen-tavneos-retraction-ema-revocation-hearing-deadline` or we can update `amgen-tavneos-regulatory-crisis-advocate-retraction`. Let's use `amgen-tavneos-retraction-ema-revocation-hearing-deadline` as it is the most recent and directly relates to the July 29 hearing deadline. Wait, let's update `amgen-tavneos-retraction-ema-revocation-hearing-deadline` to report that Amgen submitted its package on July 23, 2026. - **H5N1 bird flu in New Zealand and Australia:** This is a major escalation! New Zealand confirmed its first case on July 10 (brown skua) and its second case on July 17 (kāhu / swamp harrier), indicating local transmission. Australia's wild bird cases grew to 17, and Queensland reported its first case (petrel) on July 25. Subantarctic Heard Island elephant seal pup mortality was reported in June (13,000 dead). We can update `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` or `h5n1-avian-influenza-arrival-new-zealand` with this incredibly fresh information. Let's update `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` as it captures the "flockdown" and the arrival in both countries. - **US Cyclospora Outbreak Expansion:** The CDC expanded the outbreak to 9 states on July 24, with cases surging to 1,947. A second separate outbreak of 72 cases is also under investigation. The FDA reclassified a positive test on Taylor Farms lettuce as a false positive, but the epidemiological link remains strong, and Taylor Farms has suspended central Mexico operations. We will update `cyclosporiasis-michigan-multistate-outbreak-2026` to reflect this. Wait! Let's double check if there are any other notes we should update. Let's see our prior notes from `read_notes`: - `fda-crl-public-disclosure-policy` - `amgen-tavneos-retraction-ema-revocation-hearing-deadline` - `hhs-clinical-trials-reform-operation-trailblazer` - `fda-precheck-pilot-program-domestic-manufacturing` - `tolebrutinib-eu-approval-fda-regulatory-divergence` - `omeros-narsoplimab-ema-rejection-regulatory-divide` - `unicycive-therapeutics-oxylanthanum-carbonate-crl` - `sobi-nasp-gout-fda-crl-manufacturing` - `sanofi-sarclisa-escena-subcutaneous-on-body-injector-myeloma` - `pfizer-hympavzi-hemophilia-prophylaxis` - `fda-regulatory-pivot-advisory-committees-capricor-replimune` - `cyclosporiasis-michigan-multistate-outbreak-2026` - `hengrui-elevar-camrelizumab-rivoceranib-fda-crl` - `nejm-retracts-tavneos-advocate-trial-paper-amgen-fda-ema-withdrawal` - `amgen-tavneos-chmp-revocation-data-integrity` - `h5n1-avian-influenza-arrival-new-zealand` - `saol-sl1009-dca-fda-resubmission` - `amgen-tavneos-regulatory-crisis-advocate-retraction` - `hhs-clinical-trials-reform-operation-trailblazer` - `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` - `vera-trutakna-fda-accelerated-approval-igan` - `australia-h5n1-avian-influenza-seabirds` - `2026-world-cup-measles-outbreak-risks` - `h5n1-bird-flu-arrival-australia-new-zealand` - `cambridge-diosynvax-ai-designed-vaccine` - `amgen-tavneos-fda-hearing-nejm-retraction` - `hhs-ends-covid-19-emergency-use-authorizations` - `omeros-narsoplimab-chmp-negative-opinion-ta-tma` - `new-world-screwworm-us-outbreak` - `achieve-life-sciences-cytisinicline-crl-manufacturing-transition` - `capricor-deramiocel-ns-pharma-dispute` - `h5n1-avian-influenza-australia-local-transmission` - `gedatolisib-revtorpyk-fda-approval-breast-cancer` - `australia-h5n1-wildlife-transmission` - `bundibugyo-ebola-outbreak-drc-uganda` - `uniqure-amt-130-huntington-disease-bla-path` - `celcuity-gedatolisib-fda-pdufa-breast-cancer` - `huntingtons-disease-gene-silencing-roche-tominersen-setback` - `amgen-tavneos-eu-revocation-us-fda-extension` - `fda-istand-first-in-silico-drug-development-tool` - `kailera-obesity-pipeline-hrs-7535` - `eplontersen-wainua-cardio-ttransform-trial` - `revolution-medicines-daraxonrasib-pancreatic-cancer` - `vera-therapeutics-trutakna-fda-accelerated-approval-igan` - `e-coli-frozen-blueberries-publix-multistate-outbreak-2026` - `australia-h5n1-avian-influenza-wild-birds-nsw-east-coast-expansion` - `h5n1-avian-influenza-arrival-australia` - `casgevy-fda-approval-expansion-pediatric-scd-tdt` - `amgen-tavneos-fda-scrutiny-withdrawal-dispute` - `fda-approval-skyrizi-pediatric-psoriasis-arthritis` Let's organize the notes we'll write or update: 1. **Amgen Tavneos Update:** - Slug: `amgen-tavneos-retraction-ema-revocation-hearing-deadline` - Title: `Amgen's Tavneos Faces Retraction and EMA Revocation Ahead of Critical FDA Hearing Deadline` (We can reuse this slug and title or slightly adjust the title since the deadline is resolved by the submission). Let's keep the slug `amgen-tavneos-retraction-ema-revocation-hearing-deadline`. - Content: Detail the July 23, 2026 submission. Mention the Duke Clinical Research Institute (DCRI) re-adjudication, the loss of superiority at Week 52 (though noninferiority was preserved), real-world evidence, and hepatic safety data (including Japan's older cohorts and the fatal VBDS cases). 2. **H5N1 Bird Flu Oceania Update:** - Slug: `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` - Title: `H5N1 Avian Influenza Breaches New Zealand: First Native Bird Case and Poultry "Flockdown" Imposed` - Content: Detail the first NZ case on July 10 (brown skua Petone Beach) and the second NZ case on July 17 (kāhu / swamp harrier north of Wellington in Carterton, Wairarapa). Emphasize that the kāhu is a resident land predator, raising fears of undetected local transmission. Mention the voluntary "flockdown" of free-range hens in NZ, DOC's vaccination of 300 critically endangered native birds (kākāpō), and Queensland's first case (petrel found on Moreton Island) on July 25. Include the June 2026 Australian Antarctic Program report about 13,000 dead elephant seal pups on Heard Island. 3. **US Cyclospora Outbreak Update:** - Slug: `cyclosporiasis-michigan-multistate-outbreak-2026` - Title: `Domestic Cyclospora Outbreak Surges Past 4,000 Cases as Investigation Focuses on Taylor Farms and New Unspecified Source Outbreak` (We will update this) - Content: Detail the CDC's July 24 expansion to 9 states (adding Illinois, Indiana, Kansas, Oklahoma, Pennsylvania). Cases linked specifically to this Taylor Farms outbreak have reached 1,947, with 98 hospitalizations. Nationally, overall cases are approaching 7,000. Mention the second separate outbreak of 72 cases announced by the FDA on July 22. Detail the FDA's false-positive correction for the July 18 sample, but emphasize that traceback and epidemiological data remain robustly linked to Taylor Farms de Mexico lettuce at Taco Bell, leading to a voluntary recall and shutdown of the facility in central Mexico. 4. **Outlook Therapeutics Lytenava Approval:** - Slug: `outlook-therapeutics-lytenava-fda-approval` - Title: `FDA Approves Outlook Therapeutics' Lytenava as First Ophthalmic Bevacizumab for Wet AMD` - Content: Detail the July 24, 2026 approval of Lytenava (bevacizumab-vikg) for wet AMD. Explain why this is a major milestone: bevacizumab has been widely used off-label for over two decades in retina care, but required compounding pharmacies (which had safety/quality issues). Lytenava is the first purpose-built, regulated ophthalmic formulation, with an estimated 12 years of market exclusivity under the BPCIA. Mention Bob Jahr's quote and the $8.5 billion U.S. retina market setup. 5. **Nuvalent Jideytro Approval (Optional but very on-topic as a major approval):** - Slug: `nuvalent-jideytro-zidesamtinib-fda-approval` - Title: `FDA Approves Nuvalent's Jideytro (zidesamtinib) for ROS1-Positive NSCLC` - Content: Detail the July 22, 2026 approval of Jideytro (zidesamtinib) to treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) after receiving a ROS1 kinase inhibitor. It was approved two months ahead of its projected schedule. Let's begin writing these notes! Let's write them carefully, grounding them in the exact sources and quotes. Wait, let's write the Amgen Tavneos note first. Let's see: Slug: `amgen-tavneos-retraction-ema-revocation-hearing-deadline` We will use the exact slug to update the note. Let's write the markdown body. No YAML frontmatter. The first line is `# <Title>`. The Sources block must be at the bottom. We must include 1-2 verbatim quotes. Let's double-check the exact DCRI re-adjudication numbers from Amgen's statement: "The independent 2026 re-adjudication confirmed noninferiority of TAVNEOS versus a prednisone taper for remission at Week 26 (68.1% vs 67.1%; difference, 2.2%; 95% CI, −7.5 to 11.9) and sustained remission at Week 52 (61.4% vs 52.4%; difference, 9.8%; 95% CI, −0.3 to 19.9). ... Although superiority was not demonstrated at week 52 in the TAVNEOS arm vs. prednisone taper arm, in contrast to the original analysis, the overall findings remained similar to the original ADVOCATE results with a treatment effect that directionally favored TAVNEOS for sustained remission (re-adjudication week 52 difference 9.8% [95% CI, −0.3 to 19.9] and original week 52 difference 12.5% [95% CI, 2.6% to 22.3%] for TAVNEOS vs prednisone taper)." Let's look at the safety data: "serious hepatic adverse events were reported at a rate of approximately 31 events per 1,000 patient-years. Most reported hepatic events were reversible laboratory abnormalities; however, serious liver injury and vanishing bile duct syndrome (VBDS), including fatal outcomes, were reported, predominantly from Japan in patients > 65 years old." Let's write this note now.I will write a detailed finding updating the Amgen Tavneos regulatory crisis, using the existing slug `amgen-tavneos-retraction-ema-revocation-hearing-deadline`. This note will detail Amgen's formal submission of its data package to the FDA on July 23, 2026, ahead of the July 29 hearing deadline, including the results of the Duke Clinical Research Institute's independent re-adjudication of the Phase 3 ADVOCATE trial.

I will now update the existing note on Amgen's Tavneos regulatory crisis with the new details of their July 23, 2026 FDA submission, including the results of the Duke Clinical Research Institute's independent re-adjudication of the Phase 3 ADVOCATE trial. This is written to the stable slug `amgen-tavneos-retraction-ema-revocation-hearing-deadline`.

I will now write a detailed update for the H5N1 bird flu situation in Oceania, using the existing stable slug `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns`. This note will detail the critical escalation represented by New Zealand's second confirmed case (a resident kāhu / swamp harrier), the voluntary poultry "flockdown" in New Zealand, Queensland's first wild bird case, and the subantarctic seal mortality data.

I will now write an update for the US Cyclospora outbreak, using the existing stable slug `cyclosporiasis-michigan-multistate-outbreak-2026`. This note will detail the CDC's expansion of the outbreak to 9 states, the surge in cases to 1,947, the FDA's reclassification of a positive test as a false positive, and the investigation of a second separate outbreak of 72 cases.

I will now write a fresh note detailing the historic FDA approval of Outlook Therapeutics' Lytenava (bevacizumab-vikg) on July 24, 2026. This note will use the stable slug `outlook-therapeutics-lytenava-fda-approval`. This represents a major structural shift for the $8.5 billion U.S. retina market.

I will now write a fresh note detailing the FDA approval of Nuvalent's ROS1 lung cancer drug, Jideytro (zidesamtinib), on July 22, 2026. This note will use the stable slug `nuvalent-jideytro-zidesamtinib-fda-approval`. This represents a major regulatory win for Nuvalent, occurring two months ahead of its projected schedule.

I have written all the findings worth keeping: 1. Updated `amgen-tavneos-retraction-ema-revocation-hearing-deadline` on Amgen's Tavneos FDA submission. 2. Updated `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` on the H5N1 bird flu situation in Oceania (first native land bird case in NZ, voluntary poultry flockdowns, QLD bird detection, subantarctic elephant seal pup deaths). 3. Updated `cyclosporiasis-michigan-multistate-outbreak-2026` on the US Cyclospora outbreak (CDC's expansion to 9 states, 1,947 cases, the false positive sample correction, and a second separate outbreak of 72 cases). 4. Minted a fresh note `outlook-therapeutics-lytenava-fda-approval` for the landmark FDA approval of Outlook's Lytenava. 5. Minted a fresh note `nuvalent-jideytro-zidesamtinib-fda-approval` for the early FDA approval of Nuvalent's Jideytro. Let's check if there are any threads we can resolve or record. Wait, let's see if there are any watches or threads that have been resolved. Looking at our threads: - No threads have been fully resolved (the watches for Capricor, Replimune, Saol, etc. are still oncoming, as their dates or meetings are scheduled for late July/August 2026 or later). - Wait, what about the Outlook Therapeutics Lytenava approval? We didn't have a specific watch for it, but it represents a massive approval. - Is there any other thread or watch to record? No, we have registered plenty of high-quality watches in past cycles that are still active and tracking. I will now call `finish_cycle` to complete this research cycle.

I have successfully completed the research cycle for this topic. Here is a summary of the critical updates and breakthroughs documented during this cycle: ### 1. Amgen’s Tavneos FDA Submission (Stable Slug: `amgen-tavneos-retraction-ema-revocation-hearing-deadline`) * **What Happened:** On July 23, 2026, Amgen submitted an extensive data package to the FDA to challenge the proposed withdrawal of **Tavneos (avacopan)**, ahead of the July 29 administrative deadline. * **The Findings:** The core of the package is an independent, blinded re-adjudication of the Phase 3 ADVOCATE trial conducted by the **Duke Clinical Research Institute (DCRI)**. The re-adjudication confirmed noninferiority of Tavneos vs. prednisone taper for remission at Week 26 (68.1% vs. 67.1%) and Week 52 (61.4% vs. 52.4%). Crucially, **statistical superiority was not replicated at Week 52** in the re-adjudication, crossing zero with a 95% CI of −0.3 to 19.9 (in contrast to the original, manipulated analysis that claimed superiority). * **Safety Profile:** Amgen’s global safety database showed serious hepatic events at a rate of 31 events per 1,000 patient-years, with fatal cases of vanishing bile duct syndrome (VBDS) reported predominantly in Japanese patients over 65 years old. ### 2. H5N1 Bird Flu Oceania Escalation (Stable Slug: `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns`) * **What Happened:** The biosecurity threat has intensified. New Zealand confirmed a second H5N1 case on July 17, 2026: a **native kāhu (swamp harrier)** found inland near Carterton. * **Significance:** Because the kāhu is a resident land scavenger (not migratory), this case raises serious concerns that **undetected local transmission** is already occurring in New Zealand's wild bird population. * **Responses:** Free-range poultry farms in New Zealand have entered a voluntary **"flockdown"** (bringing hens indoors). Sanctuaries are tightening biosecurity, and the Department of Conservation is vaccinating critically endangered native birds like the **kākāpō**. * **Australia:** Detections in wild seabirds have grown to ~17, with Queensland reporting its first case (a petrel) on July 25, 2026. This follows devastating June reports from the subantarctic Heard and McDonald Islands, where H5N1 wiped out an estimated **13,000 elephant seal pups** (75% of the pup cohort). ### 3. Record-Setting U.S. Cyclospora Outbreak (Stable Slug: `cyclosporiasis-michigan-multistate-outbreak-2026`) * **What Happened:** On July 24, 2026, the CDC expanded the nation's largest recorded cyclosporiasis outbreak to **nine states** (adding IL, IN, KS, OK, and PA). Confirmed cases linked to this primary outbreak have reached **1,947**, with at least 98 hospitalizations. * **Source & Recalls:** Contaminated shredded iceberg lettuce supplied by **Taylor Farms de Mexico** (served at Taco Bell) remains the primary suspect. Taylor Farms has voluntarily recalled lettuce from central Mexico and temporarily shut down production at that facility. * **Twist & Second Outbreak:** The FDA reclassified a positive lettuce sample from July 18 as a **false positive** after a lab re-review, though the epidemiological traceback remains robust. Separately, the FDA announced a **second, independent Cyclospora outbreak of 72 cases** on July 22, 2026, with no food source identified yet. ### 4. Landmark FDA Approvals (Fresh Slugs) * **Outlook Therapeutics' Lytenava (bevacizumab-vikg) (Slug: `outlook-therapeutics-lytenava-fda-approval`):** Approved on July 24, 2026, for wet age-related macular degeneration (wet AMD). This is a monumental shift for the $8.5 billion U.S. retina market. Bevacizumab has been used off-label as a first-line treatment for over 20 years, but required compounding pharmacies (posing sterility and dosing risks). Lytenava is the first purpose-built, regulated ophthalmic formulation, carrying an anticipated 12 years of market exclusivity under the BPCIA. * **Nuvalent's Jideytro (zidesamtinib) (Slug: `nuvalent-jideytro-zidesamtinib-fda-approval`):** Approved on July 22, 2026, for ROS1-positive non-small cell lung cancer (NSCLC) post-TKI therapy. Approved two months ahead of schedule, Jideytro is a next-generation, brain-penetrant, ROS1-selective TKI designed to overcome resistance mutations (like G2032R) while avoiding the off-target neurological toxicities associated with TRK inhibition.